Search

Displaying results 2161 - 2170 of 10000 in total
  1. Drug

    Dextropropoxyphene

    go.drugbank.com/drugs/DB00647
    ApprovedIllicitWithdrawn

    The levo-isomer appears to exhibit a very limited antitussive effect. … The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  2. Drug

    Genistein

    go.drugbank.com/drugs/DB01645
    Investigational

    An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. … It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].

    Categories: Compounds used in a research, industrial, or household setting, P-glycoprotein inhibitors
  3. Drug

    Dexmedetomidine

    go.drugbank.com/drugs/DB00633
    ApprovedInvestigationalVet approved

    An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsProducts: SEMOTİDİN 200 MCG/50 ML IV İNFÜZYONLUK ÇÖZELTİ, 1 ADET, SEMOTİDİN 400 MCG/100 ML IV İNFÜZYONLUK ÇÖZELTİ, 1 ADET
  4. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    Centanafadine is a reuptake inhibitor at the norepinephrine, dopamine, and serotonin transporters and a central nervous system stimulant. … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.

  5. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD. … Phenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD.

  6. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    Lincomycin

    go.drugbank.com/drugs/DB01627
    ApprovedInvestigationalVet approved

    Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis_ in Lincoln, Nebraska. … [A190621] Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains

    Products: LINCOCIN 600 MG IM/IV AMPUL, 1 ADET
  8. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema). … Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. … [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin

  10. Drug

    Butyrfentanyl

    go.drugbank.com/drugs/DB09173
    ExperimentalIllicit

    [A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic. … [L7811] This compound is a schedule I controlled substance in the USA because it is a positional isomer of 3-Methylfentanyl.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates